Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 2/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.49 |
| ▸ | RBP4 | P02753 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1763904 | 0.90 | SLC9A1 (0.54) | SLC9A1SCN9AGPR119KDM4EMAPT | |
| SCHEMBL1039156 | 0.84 | GPR119 (0.53) | SCN9AGPR119RBP4KDM4EMAPT | |
| SCHEMBL31615908 | 0.84 | KDM4E (0.50) | SCN9AGPR119RBP4KDM4EMAPT | |
| SCHEMBL1763058 | 0.84 | SLC9A1 (0.53) | SLC9A1SCN9AGPR119STSKDM4E | |
| SCHEMBL19107668 | 0.83 | PDE4A (0.47) | SCN9AGPR119RBP4KDM4EMAPT | |
| SCHEMBL8894967 | 0.83 | VCAM1 (0.51) | SLC9A1RBP4KDM4EMAPT | |
| SCHEMBL1763753 | 0.83 | RBP4 (0.61) | SLC9A1GPR119RBP4 | |
| SCHEMBL8896458 | 0.81 | VCAM1 (0.49) | SLC9A1KDM4E | |
| SCHEMBL6606823 | 0.81 | RBP4 (0.45) | SCN9AGPR119RBP4STSKDM4E | |
| SCHEMBL19284677 | 0.81 | RBP4 (0.49) | SCN9AGPR119RBP4KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| EP-2321274-A1 | PYRROLIDINYL AND PIPERIDINYL COMPOUNDS USEFUL AS NHE-1 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010005783-A1 | PYRROLIDINYL AND PIPERIDINYL COMPOUNDS USEFUL AS NHE-1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | NHERF1, SLC9A1, SLC9A5 | SLC9A1 2/4885SCN9A 192/4885GPR119 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.